Investment Thesis
Bioventus demonstrates concerning fundamental deterioration with revenue declining and net income falling 16.7% YoY, while generating inadequate returns on equity (1.6%) and assets (0.5%). Despite strong gross margins of 68.7%, razor-thin operating (6.4%) and net margins (2.4%) combined with high leverage (1.34x D/E) and significant debt burden ($253.3M) relative to cash position ($35.8M) suggest mounting operational and financial pressure.
Strengths
- Strong gross margin of 68.7% indicates product pricing power and cost management
- Adequate liquidity position with current ratio of 1.69x and positive free cash flow of $8.4M
- Operating in medical device sector with structural growth tailwinds and high barriers to entry
Risks
- Declining revenue (-0.9% YoY) and sharply falling net income (-16.7% YoY) signal business contraction
- Extremely poor returns on equity (1.6%) and assets (0.5%) indicate inefficient capital deployment
- High financial leverage (1.34x D/E ratio) with $253.3M long-term debt against only $35.8M cash creates debt service vulnerability
Key Metrics to Watch
- Revenue growth trajectory and whether declines stabilize or accelerate
- Operating margin expansion potential given strong gross margins
- Debt reduction progress and cash flow adequacy to service debt obligations
Financial Metrics
Revenue
132.1M
Net Income
3.1M
EPS (Diluted)
$0.04
Free Cash Flow
8.4M
Total Assets
650.5M
Cash
35.8M
Profitability Ratios
Gross Margin
68.7%
Operating Margin
6.4%
Net Margin
2.4%
ROE
1.6%
ROA
0.5%
FCF Margin
6.3%
Balance Sheet & Liquidity
Current Ratio
1.69x
Quick Ratio
1.13x
Debt/Equity
1.34x
Debt/Assets
64.0%
Interest Coverage
N/A
Long-term Debt
253.3M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-07T08:16:54.245207 |
Data as of: 2026-03-28 |
Powered by Claude AI